Skip to main content
Premium Trial:

Request an Annual Quote

Cellectricon s Dynaflow Proficient (Pro) System, Dynaflow 48-channel chip, Dynaflow 16-channel chip, and Dynaflow Commander Pro 1.0, and Research and Markets High-Content Analysis Market Outlook Report


Cellectricon last week announced the launch of the Dynaflow Proficient (Pro) System for increased throughput in ion channel drug screening. The launch comes following a beta-testing period completed by GlaxoSmithKline, Cellectricon said.

The Dynaflow Pro System can be used together with the new Dynaflow 48-channel chip and the existing Dynaflow 16-channel chip. New control software, the Dynaflow Commander Pro 1.0, is compatible with both chips. The Dynaflow 48 makes it possible to receive multiple compound dose responses per chip and per cell — up to 12 full dose response curves per day, Cellectricon said. The Dynaflow 16 can be used to extract up to five full dose responses from single cells in a day, the company said.

Research and Markets has announced the availability of a new report, High-Content Analysis Market Outlook.

According to Research and Markets, the report provides:

• an overview of the current state of cell-based assays in drug development;

• a profile of the high-content analysis customer and an analysis of factors influencing the adoption of HCS technology;

• a five-year projection of spending on new equipment and reagents;

• and the impact of high-content analysis on systems biology.

The report can be found at:

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.